Risk factors for recurrence after 5-year endocrine therapy in postoperative breast cancer patients
10.3760/cma.j.issn.1007-631X.2018.04.009
- VernacularTitle:乳腺癌术后内分泌治疗5年复发危险因素分析
- Author:
Fangbin SONG
1
;
Jianbing ZHANG
;
Shanbao LI
;
Junyi WU
;
Ye WANG
;
Jun QIN
;
Tao JIN
;
Junming XU
Author Information
1. 200080,上海交通大学附属第一人民医院普外科
- Keywords:
Breast neoplasms;
Prognosis;
Endocrine therapy;
Molecular subtype
- From:
Chinese Journal of General Surgery
2018;33(4):305-308
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate recurrence risk factors in postoperative breast cancer patients after 5-year adjuvant endocrine therapy.Methods From Jan 2006 to Dec 2011,a total of 327 patients were enrolled for this study.Kaplan-Meier curves were applied to estimate survival rates and COX's proportional hazards model to identify prognostic variables.Results Among these 327 eligible patients,42 (12.8％) patients suffered from distant metastasis and 34 (10.4％) patients experienced locoregional recurrence after 5-year adjuvant endocrine therapy.Survival analysis showed that patients with histologic grade 3 disease,lymph node metastasis,Ki-67 high expression,high TNM stage and radiotherapy were statistically significant with poorer relapse-free survival (RFS,P =0.000,0.003,0.000,0.003,0.034)and poorer distant metastasis-free survival (DMFS,P =0.000,0.002,0.000,0.002,0.023),respectively.In multivariate analysis,patients with histological grade 3 disease (P =0.002) and more than 3 positive nodes (P =0.032) were risk factors for lower RFS.However,only histological grade 3 (P =0.015) was risk factor for DMFS.Conclusions Late relapse after completion of 5-year adjuvant endocrine therapy was still common,patients with grade 3 disease and more than 3 positive nodes may benefit from extended endocrine therapy.
